Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for XmAb819 (ENPP3 x CD3) in Clear cell renal cell carcinoma (ccRCC). The expected timing is based on the latest available company guidance and may change.
9/9/24- Encouraging clinical activity in Ph1. 10/24/25- Presented dose-escalation results AACR-NCI-EORTC'25. 11/05/25:- Ph1 dose-escalation and first expansion cohort ongoing; plan Phase 3 dose selection in 2026, pivotal study 2027. 01/08/26:- Ph1 showed 25% PR rate, 70% disease control; new RP3D-supporting data planned in H2 2026. 02/26/26:- Dose expansion in CRC, NSCLC and pRCC enrolling; plan Ph1 data supporting RP3D in H2 2026. 05/06/26:- Expansion cohort data in ccRCC to be presented 2H26; TKI-naive ccRCC sub-study initiation planned 3Q26. 08/05/26:- ESMO 2026 oral data planned; new sub-studies are enrolling or planned.
Verification
Confirm timing and program details against the company announcement or filing.